Evidence map›Paper›PMID 41497507›Full record

ArticleEClinicalMedicine2025

Incidence of non-colorectal/endometrial malignancies in individuals with Lynch syndrome: a retrospective cohort study.

Silvia Negro, Francesco Celotto, Francesca Schiavi, Marco Scarpa, Isabella Mammi, Silvia Rossi, Lorenzo Dell'Atti, Maria Caterina De Grandis, Gino Crivellari, Matteo Fassan and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Silvia NegroThird Surgery Unit, Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Padua, Italy.
Francesco CelottoThird Surgery Unit, Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Padua, Italy.
Francesca SchiaviFamilial Cancer Clinic and Oncoendocrinology, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Marco ScarpaThird Surgery Unit, Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Padua, Italy.
Isabella MammiFamilial Cancer Clinic and Oncoendocrinology, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Silvia RossiFamilial Cancer Clinic and Oncoendocrinology, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Lorenzo Dell'AttiThird Surgery Unit, Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Padua, Italy.
Maria Caterina De GrandisMedical Oncology Unit 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Gino CrivellariFamilial Cancer Clinic and Oncoendocrinology, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Matteo FassanSurgical Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padua, Padua, Italy.
Marco AgostiniThird Surgery Unit, Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Padua, Italy.
Gaya SpolveratoThird Surgery Unit, Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Padua, Italy.
Filippo CappelloDepartment of Pathology, Azienda Ospedale Università Padova, Padua, Italy.
Edoardo D'AngeloThird Surgery Unit, Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Padua, Italy.
Michele MilellaDepartment of Engineering for Innovative Medicine and Hospital of Trust of Verona, Oncology Section, Verona, Italy.
Maria BencivengaGeneral and Upper GI Surgery Unit, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona, Verona, Italy.
Pierluigi PilatiSurgical Oncology of the Digestive Tract, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Sara LonardiMedical Oncology Unit 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Rossana IntiniMedical Oncology Unit 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Valentina GuarneriMedical Oncology Unit 2, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Maria Vittoria DieciMedical Oncology Unit 2, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Alberto MorabitoDepartment of Oncology, Azienda ULSS 6 'Euganea', Cittadella, Italy.
Daniela BaranaOncology Unit, Local Health and Social Care Unit, ULSS8 Berica, Montecchio Maggiore, Italy.
Alessandra D'UrsoPathology Unit, AULSS1 Dolomiti, Feltre, Italy.
Massimo IafrateUrology Clinic, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy.
Francesca BergamoMedical Oncology Unit 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Emanuele D L UrsoThird Surgery Unit, Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lynch syndrome (LS) is strongly associated with colorectal (CRC) and endometrial (EC) cancers, for which Universal Tumor Screening (UTS) via mismatch repair proteins (MMRs) immunohistochemistry is currently recommended. However, emerging evidence suggests an association between LS and several other tumor types. We therefore evaluate the incidence of non-CRC/ECs in LS individuals. Methods: A retrospective analysis of 570 patients with LS diagnosed between 1995 and 2023 was performed (Ethics approval: AOP3125, July 27, 2023). Patients were stratified based on MMR gene mutations. Clinical data, including cancer type, age at diagnosis, and time to LS confirmation, were analyzed. Findings: Non-CRC/ECs accounted for 40% (228/573) of all malignancies. The most common types were urothelial/kidney (8%), breast (8%), ovarian (6%) and gastric (4%) cancers. The highest SIRs were observed for cancers of the small intestine [SIR: 10.54; 95% CI: 5.90-17.39], urothelium/kidney [7.55; 95% CI: 5.42-10.24], gastric [4.68; 95% CI: 2.90-7.16], ovary [3.80; 95% CI: 2.32-5.87], and pancreas [3.09; 95% CI: 1.69-5.18]. Among the 63 (11%) patients diagnosed with non-CRC/ECs before genetic testing, 29 (46%) later developed CRC or EC, with a median time to onset of 10 years for CRC (IQR: 5-15) and 6 years for EC (IQR: 2-9). Interpretation: The findings show that 40% of patients had non-CRC/ECs, with 11% of these cases diagnosed prior to undergoing genetic testing. Prospective studies with MMRs immunohistochemistry on all tumors arising in Lynch patients are needed to confirm our results and to explore the cost-effectiveness and feasibility of implementing broader screening strategies. Funding: None.

Indexed as

Extracolonic malignanciesLynch syndromeMismatch repair genesNon-colorectal/endometrial tumorsUniversal tumor screening

Identifiers

PMID41497507
PMCPMC12766425

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.